281 related articles for article (PubMed ID: 30714167)
21. Evaluation of circulating EBV microRNA BART2-5p in facilitating early detection and screening of nasopharyngeal carcinoma.
Jiang C; Chen J; Xie S; Zhang L; Xiang Y; Lung M; Kam NW; Kwong DL; Cao S; Guan XY
Int J Cancer; 2018 Dec; 143(12):3209-3217. PubMed ID: 29971780
[TBL] [Abstract][Full Text] [Related]
22. Quantification of Epstein-Barr virus DNA load, interleukin-6, interleukin-10, transforming growth factor-beta1 and stem cell factor in plasma of patients with nasopharyngeal carcinoma.
Tan EL; Selvaratnam G; Kananathan R; Sam CK
BMC Cancer; 2006 Sep; 6():227. PubMed ID: 16995954
[TBL] [Abstract][Full Text] [Related]
23. Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China.
Zheng XH; Lu LX; Li XZ; Jia WH
Cancer Sci; 2015 Sep; 106(9):1196-201. PubMed ID: 26082292
[TBL] [Abstract][Full Text] [Related]
24. Application of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma.
Yip TT; Ngan RK; Fong AH; Law SC
Oral Oncol; 2014 Jun; 50(6):527-38. PubMed ID: 24440146
[TBL] [Abstract][Full Text] [Related]
25. Multiplex Epstein-Barr virus BALF2 genotyping detects high-risk variants in plasma for population screening of nasopharyngeal carcinoma.
Miller JA; Sahoo MK; Yamamoto F; Huang C; Wang H; Zehnder JL; Le QT; Pinsky BA
Mol Cancer; 2022 Jul; 21(1):154. PubMed ID: 35902864
[TBL] [Abstract][Full Text] [Related]
26. [Quantitative analysis of plasma Epstein-Barr virus (EBV) DNA for monitoring of recurrence and metastasis in nasopharyngeal carcinoma patients after radiotherapy].
Li YH; Shao JY; Zhao MQ; Gao HY; Li LR; Guan ZZ; Zeng YX
Ai Zheng; 2003 Jun; 22(6):645-8. PubMed ID: 12948418
[TBL] [Abstract][Full Text] [Related]
27. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.
Leung SF; Chan AT; Zee B; Ma B; Chan LY; Johnson PJ; Lo YM
Cancer; 2003 Jul; 98(2):288-91. PubMed ID: 12872347
[TBL] [Abstract][Full Text] [Related]
28. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody.
Leung SF; Tam JS; Chan AT; Zee B; Chan LY; Huang DP; Van Hasselt A; Johnson PJ; Lo YM
Clin Chem; 2004 Feb; 50(2):339-45. PubMed ID: 14684618
[TBL] [Abstract][Full Text] [Related]
29. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
[TBL] [Abstract][Full Text] [Related]
30. Vesicle-bound EBV-BART13-3p miRNA in circulation distinguishes nasopharyngeal from other head and neck cancer and asymptomatic EBV-infections.
Ramayanti O; Verkuijlen SAWM; Novianti P; Scheepbouwer C; Misovic B; Koppers-Lalic D; van Weering J; Beckers L; Adham M; Martorelli D; Middeldorp JM; Pegtel DM
Int J Cancer; 2019 May; 144(10):2555-2566. PubMed ID: 30411781
[TBL] [Abstract][Full Text] [Related]
31. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of plasma Epstein-Barr virus DNA load as a prognostic marker for nasopharyngeal carcinoma.
Tan EL; Looi LM; Sam CK
Singapore Med J; 2006 Sep; 47(9):803-7. PubMed ID: 16924363
[TBL] [Abstract][Full Text] [Related]
33. Serum/plasma viral DNA: mechanisms and diagnostic applications to nasopharyngeal and cervical carcinoma.
Mutirangura A
Ann N Y Acad Sci; 2001 Sep; 945():59-67. PubMed ID: 11708495
[TBL] [Abstract][Full Text] [Related]
34. The role of plasma Epstein-Barr virus DNA in the management of recurrent nasopharyngeal carcinoma.
Chan JY; Wong ST
Laryngoscope; 2014 Jan; 124(1):126-30. PubMed ID: 23686740
[TBL] [Abstract][Full Text] [Related]
35. High-sensitivity C-reactive protein complements plasma Epstein-Barr virus deoxyribonucleic acid prognostication in nasopharyngeal carcinoma: a large-scale retrospective and prospective cohort study.
Tang LQ; Li CF; Chen QY; Zhang L; Lai XP; He Y; Xu YX; Hu DP; Wen SH; Peng YT; Chen WH; Liu H; Guo SS; Liu LT; Li J; Zhang JP; Guo L; Zhao C; Cao KJ; Qian CN; Zeng YX; Guo X; Mai HQ; Zeng MS
Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):325-36. PubMed ID: 25482300
[TBL] [Abstract][Full Text] [Related]
36. Clinical Utility of Epstein-Barr Virus DNA Testing in the Treatment of Nasopharyngeal Carcinoma Patients.
Kim KY; Le QT; Yom SS; Ng RHW; Chan KCA; Bratman SV; Welch JJ; Divi RL; Petryshyn RA; Conley BA
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):996-1001. PubMed ID: 28721913
[TBL] [Abstract][Full Text] [Related]
37. Prognostic implication of pretreatment plasma/serum concentration of Epstein-Barr virus DNA in nasopharyngeal carcinoma.
Lo YM
Biomed Pharmacother; 2001 Sep; 55(7):362-5. PubMed ID: 11669497
[TBL] [Abstract][Full Text] [Related]
38. [Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma].
Cao SM; Min HQ; Gao JS; Hong MH; Xiao XB; Zhang CQ; Liu XD; Zhang AL; Guo X
Ai Zheng; 2003 Mar; 22(3):302-6. PubMed ID: 12654192
[TBL] [Abstract][Full Text] [Related]
39. Comparison of clinical and molecular surveillance in patients with advanced nasopharyngeal carcinoma after primary therapy: the potential role of quantitative analysis of circulating Epstein-Barr virus DNA.
Hong RL; Lin CY; Ting LL; Ko JY; Hsu MM
Cancer; 2004 Apr; 100(7):1429-37. PubMed ID: 15042677
[TBL] [Abstract][Full Text] [Related]
40. Nasopharyngeal Epstein-Barr Virus Load: An Efficient Supplementary Method for Population-Based Nasopharyngeal Carcinoma Screening.
Chen Y; Zhao W; Lin L; Xiao X; Zhou X; Ming H; Huang T; Liao J; Li Y; Zeng X; Huang G; Ye W; Zhang Z
PLoS One; 2015; 10(7):e0132669. PubMed ID: 26151639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
